PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Endocyte Announces Presentation of Phase 2 Data from Investigator-Initiated Prostate Cancer Trial of 177Lu-PSMA-617 at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
  – PSA response rates in additional 20 mCRPC patients enrolled at Peter MacCallum Cancer Centre higher than previously reported for first group of 30 patients – – Company to host and webcast investor event featuring physician panel on 177 Lu-PSMA-617 – WEST LAFAYETTE, Ind.
View HTML
Toggle Summary Endocyte Provides First Quarter 2018 Financial Results and Operational Update
-Recently Updated Phase 2 Data on 177 Lu-PSMA-617 Published in The Lancet Oncology Favorable to Preliminary Data Presented at 2017 ESMO Congress -        -Positive End of Phase 2 FDA Meeting Set Stage for Successful Financing in First Quarter-                -Phase 3 VISION Trial on Track for First
View HTML
Toggle Summary Endocyte Announces The Lancet Oncology Publication of Phase 2 Data From Investigator-Initiated Prostate Cancer Trial of (177)Lu-PSMA-617
-Publication includes analysis of original 30 patients previously presented at 2017 ESMO by Professor Michael Hofman of Peter MacCallum Cancer Centre -                -Relative to previously presented data, publication reflects longer median overall survival, longer median prostate specific antigen
View HTML
Toggle Summary Endocyte Announces First Quarter 2018 Earnings Call
WEST LAFAYETTE, Ind. , May 02, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that the company will host a conference call on Wednesday, May 9th , at 8:30 a.m.
View HTML
Toggle Summary Endocyte to Present at Deutsche Bank's 43rd Annual Health Care Conference
WEST LAFAYETTE, Ind. , May 01, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that the company’s management team will present at Deutsche Bank’s 43 rd Annual Health Care
View HTML
Toggle Summary Endocyte Presents Data from its CAR T Platform at American Association for Cancer Research (AACR) Annual Meeting 2018
Late-breaking poster demonstrates EC17/CAR T-cell therapy showed consistent antitumor activity in human xenografts with multiple mechanisms for controlling immune response WEST LAFAYETTE, Ind. , April 16, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing
View HTML
Toggle Summary Endocyte Announces Presentations at American Association for Cancer Research (AACR) Annual Meeting 2018
WEST LAFAYETTE, Ind. , March 15, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that four posters will be presented by Endocyte scientists at the American Association for Cancer
View HTML
Toggle Summary Endocyte Nominates Dawn Svoronos for Election to Its Board of Directors and Announces Other Board Developments
Dawn Svoronos, Former President of Merck’s Europe/Canada Region, Brings Significant Commercial Leadership and Board Experience WEST LAFAYETTE, Ind. , March 15, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer
View HTML
Toggle Summary Endocyte to Present at the Cowen and Company 38th Annual Health Care Conference
WEST LAFAYETTE, March 05, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment , today announced that the company’s management team will present at the Cowen and Company 38 th Annual Health Care
View HTML
Toggle Summary Endocyte Announces Closing of Public Offering of Common Stock
WEST LAFAYETTE, March 02, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, announced today the closing of an underwritten registered public offering of 20,535,714 shares of its common stock,
View HTML